(RTTNews) - Jade Biosciences, Inc. (JBIO) announced preclinical data for JADE301, an investigational, anti-IFN-Beta monoclonal antibody being developed for dermatomyositis, a rare autoimmune disease that can cause skin inflammation and muscle weakness.
(RTTNews) - Jade Biosciences, Inc. (JBIO) announced preclinical data for JADE301, an investigational, anti-IFN-Beta monoclonal antibody being developed for dermatomyositis, a rare autoimmune disease that can cause skin inflammation and muscle weakness.
Across all age and income groups examined in new research, the share of individuals transferring money from investment accounts to checking accounts has risen.
T-Mobile offers discounted plans for customers 55 and older, military members, veterans and first responders. See who qualifies and how much you could save.
(RTTNews) - Immunome, Inc. (IMNM), a clinical-stage targeted oncology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IM-1340, a potential first-in-class antibody-drug conjugate (ADC) for treating
With the United States leading 3-2, Borussia Dortmund teenager Mathis Albert put the game away with the Americans' fourth goal of the night and became the youngest goal scorer in program history, besting a mark set by Christian Pulisic.
(RTTNews) - Rafael Holdings (RFL) reported topline results from the pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo in patients with Niemann-Pick Disease Type C (NPC).
During the MAHA Summit, Vice President JD Vance jokes about his love of ice cream while answering Health and Human Services Secretary Robert F. Kennedy Jr.'s humorous question about his office's reported involvement in federal nutrition guidance.
The data on Novo's Wegovy pill suggests that patients may not need to take weekly injections forever, but can instead opt for more convenient treatments.
The data on Novo's Wegovy pill suggests that patients may not need to take weekly injections forever, but can instead opt for more convenient treatments.
The data on Novo's Wegovy pill suggests that patients may not need to take weekly injections forever, but can instead opt for more convenient treatments.
The data on Novo's Wegovy pill suggests that patients may not need to take weekly injections forever, but can instead opt for more convenient treatments.
(RTTNews) - A liver-focused RNA medicine candidate from Wave Life Sciences (WVE) is moving into GSK's development pipeline, triggering a $12 million milestone payment to Wave under their research collaboration.